Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.
|Videos|March 22, 2016
Jason R. Gotlib on JAK Inhibitors for the Treatment of Myelofibrosis
Author(s)Jason R. Gotlib
Jason R. Gotlib discusses JAK inhibitors for the treatment of patients with myelofibrosis.
Advertisement
Jason R. Gotlib, associate professor of Medicine (Hematology) at Stanford University Medical Center, discusses JAK inhibitors for the treatment of patients with myelofibrosis.
Gotlib discusses whether next-generation JAK inhibitors should be used after resistance to Jakafi (ruxolitinib) or in the frontline setting. Gotlib also provided an overview of drugs that are being studied in combination with these agents.
Gotlib is a
Advertisement
Related to this article
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.
Dr. Diego Schaps discussed how upcoming Medicare competitive bidding changes could affect access to ostomy supplies and why having the right pouching system matters for patients.
Advertisement
Advertisement